Award
Fred Hutchinson Cancer Center 5UH3HL147011-06
1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis
Recipient
FRED HUTCHINSON CANCER CENTER
Award Amount
$2,170,027.00
Ceiling
$2,170,027.00
Awarded
September 09, 2024
Identifier
5UH3HL147011-06
NIH-funded clinical trial to evaluate ganciclovir for preventing cytomegalovirus reactivation in patients with acute respiratory failure and sepsis, aiming to improve clinical outcomes.
Description
This is a NIH-funded clinical trial project focusing on the use of ganciclovir to prevent CMV reactivation in patients with sepsis-associated respiratory failure. The project involves multiple clinical sites and aims to improve clinical outcomes through a phase 3 randomized controlled trial.